Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 CAD | -1.99% | +7.66% | +168.18% |
14/05 | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
22/04 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+168.18% | 15Cr | |
+29.03% | 4.82TCr | |
-0.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+11.48% | 2.56TCr | |
-22.74% | 1.9TCr | |
+9.06% | 1.29TCr | |
+30.01% | 1.2TCr | |
-1.51% | 1.18TCr |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $6 From $5, Maintains Buy Rating